In light of the preclinical data that supports a role of CDK7 to enhance AR activity, at least partly through phosphorylation of MED1, and increased MED1 phosphorylation contributes to the restoration of AR activity in enzalutamide refractory prostate cancer, CDK7 becomes a potential therapeutic target in advanced CRPC. Here, MED1 is linked to prostate carcinoma.